Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.6% - Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares dropped 7.6% during trading on Monday . The company traded as low as $18.14 and last traded at $18.28. Approximately 27,802 shares changed hands during trading, a decline of 97% from the average daily volume of 840,175 shares. The stock had previously closed at $19.77.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GPCR. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities restated a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Trading Down 7.4 %

The stock's fifty day moving average price is $23.29 and its 200 day moving average price is $30.63. The stock has a market cap of $867.03 million, a P/E ratio of -20.43 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. As a group, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after acquiring an additional 553 shares during the last quarter. GAMMA Investing LLC boosted its stake in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics during the 4th quarter valued at about $34,000. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics during the 4th quarter valued at about $40,000. Finally, Virtus ETF Advisers LLC increased its stake in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.